Trial Profile
A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Multiple Escalating Oral Doses Of Pf-06427878 Co-administered With And Without Food In Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Mar 2016
Price :
$35
*
At a glance
- Drugs PF 6427878 (Primary)
- Indications Hyperlipidaemia
- Focus Adverse reactions
- Sponsors Pfizer
- 01 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Dec 2015 Planned End Date changed from 1 Nov 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov.
- 23 Dec 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov.